Clinical Trials
A clinical trial (or study) is an experiment that involves research using human volunteers and is intended to add to medical knowledge. Clinical trials involving people living with HIV are ongoing and can further our knowledge about the virus and contribute to cure research. Click on the links below to learn more about current clinical trials.
Obesity and Healthy Thinking Study
Obesity and Healthy Thinking Study This study is being done to learn if Egrifta may improve brain function in HIV positive people with abdominal obesity, which increases the risk for impaired thinking. Call Rod Hagan at 760.507.3321
Sponsor:
none
DAP Health
The mission of DAPHealth is to enhance and promote the health and well-being of our community.
Website:
Sponsor:
none
Gilead “Calibrate” NCT ID #: NCT04143594
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV
Sponsor:
Gilead
GSK “Eagle-2” NCT ID #: NCT04020341
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Sponsor:
GlaxoSmithKline
REPRIEVE Randomized Trial to Prevent Vascular Events in HIV
People living with HIV are 50–100% more likely to develop heart disease (including heart attack and stroke) than people without HIV. REPRIEVE is a clinical research trial exploring long-term prevention of heart disease among people living with HIV. Call: 1-877-29-HEART Leah Lane 760-834-7949
Website:
Sponsor:
none
Gilead “Capella” NCT ID #: NCT04150068
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance.
Sponsor:
Gilead
Merck “Illuminate” MK 8591A-018
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Sponsor:
Merck Sharp & Dohme Corp.
GSK “Eagle-1” NCT ID #: NCT04010539
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae
Sponsor:
GlaxoSmithKline
Search Current Clinical Trials
Clinicians at Eisenhower Medical Center continue to take part in groundbreaking research, including: interventional cardiology, orthopedics, novel biotherapies in oncology, targeted therapies base on molecular profile of cancer, early detection of cancer via specialized imaging, drugs aimed at improving survival of HIV patients, and use of integrative therapies to reduce side effects related to cancer treatment.
Sponsor:
none





Search Government Clinical Trials
Explore 311,636 research studies in all 50 states and in 209 countries. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.
Sponsor:
none





HIV Institute at UCSD
Active Research Studies Website
The HIV Institute at the University of California San Diego is pleased to announce the Active Research Studies website, featuring a collection of HIV and HIV-related research at the University of California San Diego.
Progress in treatment for HIV, hepatitis C, hepatitis B, tuberculosis, and other related conditions only occurs with the valuable contributions of individuals who enroll in research studies. These clinical research trials help improve the treatment and management of HIV and other infectio
Sponsor:
none





Health in Older Latinos Study
Health in Older Latinos Study
Ethnic and racial differences in the cognitive effects of HIV
3visits -3years
Latino HIV+/-
Spanish or English
Initial screen (1 hour)
Compensation up to $305
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Tesamorelin Abdominal Fat Study
Tesamorelin Abdominal Fat Study
Cognitive improvements from using Tesamorlin
1-year study
HIV+ with abdominal fat 40 y/o
Spanish or English
Multiple In-person screening visits
Immediate group or delayed group
Daily Text messaging
Self-administer medication for 6 months
5 study visits, plus phone visits
Compensation up to $635 w/ optional LPs
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Neuropathic Pain & Cannabis Study
Neuropathic Pain & Cannabis Study
Effect of cannabis on HIV neuropathic pain
6 month +
HIV+ & HIV-related Neuropathic Pain
2 components :
Daily text messaging / surveys (6 months)
Cannabis administration (3 office visits)
Initial screen (1 hour)
In-person medical screen (6-8 hours)
If eligible, enroll in either or both
Compensation up to $570
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Diet & Physical Activity Study
Diet & Physical Activity Study
Assess ways to increase moderate physical activity & improve diet
1-year study
HIV+ and able to increase moderate physical activity
Initial screen (2 hours)
2 In-person visits (6-8 hours), 1 phone visit at end
Daily text messaging (6 months)
Fit bit and accelerometer
May include Walnuts and Olive Oil
Compensation up to $465
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Nicotine and HIV Study
Nicotine and HIV Study
Effects of nicotine on the brain
1 visit – baseline only – (8 hours)
Some candidates may qualify: MRI / PET visits separately
HIV+/-
Current Smokers
Initial screen (1 hour)
1 visit - Compensation up to $90
Possible MRI and or PET scan addtional compensation up to $177.40
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Virtual Reality Assessment of How HIV Affects Cognitive and Balance Problems
Virtual Reality Assessment Study
VR assessment for Cognitive and Balance
2.5-year study
HIV+ 60+y/o
Initial screen (1 - 1 1⁄2 hours)
8 visits over 2 years
5 HNRP visits – (full & partial visits)
3 SDSU visits for hearing tests
Compensation up to $390
For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.
Sponsor:
none
Investigational HIV Treatment
Recruiting participants who have a current viral load >400 copies : Investigating PRO 140 subcutaneous injection once weekly combine with OBT in treatment experienced patients.
Sponsor:
none
idiopathic pulmonary fibrosis (IPF)
The GALACTIC-1 study will research a potential study drug that could offer benefit to patients with IPF. Thank you for considering participation in this trial.
Sponsor:
none
Illuminate HTE Clinical Trial
Illuminate HTE Study
Illuminate HTE Study a Phase 3 clinical trial evaluating an oral, once-daily investigational medication, a fixed-dose combination of doravirine/islatravir (DOR/ISL), in participants with HIV-1 who are heavily treatment experienced and failing on their current antiretroviral therapy (ART).
Sponsor:
Merck
COVID-19 STUDY FOR OUTPATIENTS
DID YOU JUST GET TESTED FOR COVID-19
but are not sick enough to be hospitalized?
Palmtree Clinical Research, Inc. (PCR, Inc.) is currently enrolling for a COVID-19 clinical trial. We are looking for patients who have recently tested positive for COVID-19.
This is an outpatient trial, 5 visits (3 in-clinic and 2 phone calls) over about a month period, with the Investigational Product being Camostat (PO, QID x 14 days).
You May Qualify If You
Just received a POSITIVE COVID-19 test result or less than 3days ago
Are at least18 years old
Do not need to be treated in the hospital right now
Can come to the clinic to sign-up and complete 2 more visits
Have just one risk factor below along with a positive COVID-19 test:
Are age 65 or older
Have diabetes mellitus (Type 1 or Type 2)
Have high blood pressure
Have chronic heart, lung, or liver disease, or
Are 35 lbs or more overweight
Participation Involves
Taking tablets for 14 days of treatment
Keeping a daily log of your temperature once a day
Three (3) short clinic visits for nasal swabs and blood draws
PARTICIPANTS WILL BE COMPENSATED FOR THEIR PARTICIPATION
CALL OR EMAIL FOR MORE INFORMATION ABOUT THE CAMELOT TRIAL Please call: 760-778-7799 Email: contact@palmtreeclinical.com
555 E Tachevah Drive, Suite 1E-201, Palm Springs, CA 92262
(Located across from Desert Regional Hospital in the Las Palmas Medical Plaza)
Sponsor:
none
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
“A 16-Week Study Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo to treat HIV-Associated Distal Sensory Polyneuropathy (DSP) in Patients with HIV (PWH)”
Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV. Abdominal fat accumulation is linked to memory and thinking difficulties, and previous studies have suggested that tesamorelin also may be beneficial for memory and thinking, but this has not been tested in HIV.
This is a randomized trial in which participants will have a 60% chance of initially receiving tesamorelin (the Immediate group) and a 40% chance of initially receiving no treatment (the Deferred group) for 6 months. Subsequently, those who initially received no treatment will receive tesamorelin and those who initially received tesamorelin will receive no treatment for 6 months.
This study includes text messaging, memory and thinking assessments, blood draws, and magnetic resonance imaging (MRI) scans of the head and abdomen.
Sponsor:
WinSanTor, Inc.
Live Healthy Study: Smoking Cessation
UCSD Live Healthy Study
Who can participate?
Persons living with HIV who smoke or recently quit smoking
What does participation involve?
Questionnaire (35-45 minutes). Compensation is $30.
AND/OR
Focus Group (1-1.5 hours). Compensation is $35.How to participate?
All participation is remotePlease click this link to complete the eligibility screener:https://tinyurl.com/yyvhuahe
(If the link does not work, please copy and paste it into your web browser)
If you are eligible, you will be invited to complete the main survey. Focus groups are conducted remotely via Zoom or phone.
Website:
Sponsor:
none
Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)”
– ACTG5391
The study, “Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)” is a randomized evaluation of Doravirine vs. other INSTI among PWH who have gained weight during their current INSTI therapy. I am enclosing a summary of the protocol details. We would love it if you could share this information with your contacts in Palm Springs? We anticipate that the study will enroll rapidly, so I have included the study coordinator emails (George and Cristina) – feel free to reach out to any of us if you have questions. Interested people can be referred to George or Cristina for more information.
Sponsor:
Gilead